New Zealand markets closed

NVO Jan 2025 100.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.87000.0000 (0.00%)
As of 01:06PM EDT. Market open.
Full screen
Previous close2.8700
Open2.8500
Bid0.0000
Ask0.0000
Strike100.00
Expiry date2025-01-17
Day's range2.8500 - 2.8700
Contract rangeN/A
Volume2
Open interestN/A
  • Yahoo Finance Video

    Apple, Novo Nordisk earnings, jobless claims: What to watch

    A number of companies release their quarterly earning reports on Thursday, including Apple (AAPL), Novo Nordisk (NVO), Shell (SHEL), ConocoPhillips (COP), Cigna (CI), Coinbase (COIN), Moderna (MRNA), DraftKings (DKNG), Kellanova (K), United States Steel (X), and more. On the economic front, jobless claims for the week ending on April 27 will be released. Economists expect claims to rise to 212,000 from 207,000 the prior week. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Nicholas Jacobino

  • Reuters

    UPDATE 3-Novo Nordisk raises outlook fuelled by obesity drug demand

    Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The company has quadrupled its U.S. supply of starter doses Wegovy since December, Senior Vice President Negelle Morris told Reuters this week. At least 20,000 new U.S. patients are starting on the weekly injection each week, reflecting the company's efforts to ramp up output, she said.

  • Reuters

    Novo Nordisk raises outlook fuelled by obesity drug demand

    LONDON (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected quarterly profits as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from rival Eli Lilly. The company has quadrupled its U.S. supply of starter doses Wegovy since December, Senior Vice President Negelle Morris told Reuters this week. At least 20,000 new U.S. patients are starting on the weekly injection each week, reflecting the company's efforts to ramp up output, she said.